Skip to main content

Table 2 The mean serum concentrations of examined cytokines in patients with IPF and sarcoidosis

From: Circulating concentration of markers of angiogenic activity in patients with sarcoidosis and idiopathic pulmonary fibrosis

  Sarcoidosis n = 43 IPF n = 17 Control group n = 20
  Mean ± SEM Mean ± SEM Mean ± SEM
  Median (95 % CI) Median (95 % CI) Median (95 % CI)
Angiopoeitin-2 221.5 ± 28.7 251.6 ± 45.6 288.8 ± 68,9762
(pg/ml) 173.5 (120.7–301.8) 237.8 (72.1–294.6) 168.7 (95.6–360.4)
Follistatin 357.6 ± 31.9 582.5 ± 64.5** 462.7 ± 89.6
(pg/ml) 346.5 (264.7–416.1) 545.8 (418.5–674.5) 291.2 (231.5–478.3)
GM-CSF 31.7 ± 4.7 67.6 ± 6.4*** 29.5 ± 5.2
(pg/ml) 15.7 (10.5–43.1) 71.1 (41.7–86.5) 24.8 (9.3–48.2)
IL-8 30.8 ± 4.0 76.3 ± 5.2*** 28.9 ± 4.7
(pg/ml) 15.8 (13.8–39.7) 79.9 (57.9–96.3) 20.7 (11.4–46.0)
PDGF-BB 5528.3 ± 551.2 8629.8 ± 869.1# 7080.1 ± 1046.6
(pg/ml) 4607.0 (3464.6–6128.8) 7178.0 (6732.8–9948.4) 5384.1 (3173.5–10040.3)
PECAM-1 2490.4 ± 232.9 3392.1 ± 376.8* 2316.9 ± 388.9
(pg/ml) 2290.7 (1693.7–2795.2) 3147.5 (2428.6–4072.6) 1798.1 (1226.1–2563,1)
VEGF 88.7 ± 7.7 120.5 ± 16.0 78.0 ± 10.8
(pg/ml) 84.1 (61.9–95.4) 94.3 (77.6–157.2) 80.1 (32.6–109.2)
  1. *p < 0.05 IPF vs sarcoidosis and vs control group
  2. **p < 0.01 IPF vs sarcoidosis and vs control group
  3. ***p < 0.001 IPF vs sarcoidosis and vs control group
  4. # p < 0.05 IPF vs sarcoidosis